Having a read of some articles they believe annual revenue will be $316m vs $379m analysts forecast. They base this on a drop in patient retention rates due to insurance not covering patients as they require tangible proof of improvement from the drug, leading to discontinuation.
Acadia, page-120
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.73 |
Change
-0.280(1.33%) |
Mkt cap ! $2.647B | |||
| Open | High | Low | Value | Volume |
| $20.87 | $21.19 | $20.70 | $6.213M | 297.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5414 | $20.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.79 | 335 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.73 |
Change
-0.280 ( 1.22 %) |
||||
| Open | High | Low | Volume | ||
| $20.99 | $21.19 | $20.69 | 94423 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| NEU (ASX) Chart |